Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Withdrawn Phase 3 Interventional

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160
View directory record Official record
Conditions
Thoracic, Pulmonary Disease
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Mesna, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 24, 2026, 5:02 AM EDT
Recruiting Phase 1 Interventional

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT04038619
View directory record Official record
Conditions
Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Interventions
Fecal Microbiota Transplantation, Loperamide
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

NCT00438464
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Interventions
Finasteride, Placebo, Prostatectomy, Laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
8
States / cities
Cleveland, Ohio • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Allogeneic Blood Stem Cell Transplantation

NCT00423709
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
Allogeneic Blood Stem Cell Transplantation, Fludarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 24, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT04752163
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

NCT05064787
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Leukemia, Multiple Myeloma, Mantle Cell Lymphoma, Follicular Lymphoma, Leukemia, Acute Lymphoblastic
Interventions
Digital Health Coaching
Behavioral
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.

NCT01173692
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Minocycline, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 24, 2026, 5:02 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

NCT03772834
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Exercise Intervention, Methylphenidate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Stretching
Behavioral · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Active, not recruiting Early Phase 1 Interventional Results available

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

NCT02603887
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

NCT01444716
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
66 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 24, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 24, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681
View directory record Official record
Conditions
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Interventions
Futibatinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Recruiting No phase listed Observational

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

NCT00816114
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Results available

Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

NCT01902966
View directory record Official record
Conditions
Cervical Cancer
Interventions
Propranolol, Diary, Relaxation Audio Recording, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 24, 2026, 5:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study

NCT03408353
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Mammography, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 80 Years · Female only
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Active, not recruiting Not applicable Interventional

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

NCT07874828
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
Tirzepatide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Early Phase 1 Interventional

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

NCT02113657
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

NCT02366130
View directory record Official record
Conditions
Breast Cancer
Interventions
Ra-223 dichloride, Denosumab, Hormone Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 24, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Exemestane-RAD001-Metformin

NCT01627067
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 24, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer

NCT03445572
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Best Practice, Meditation Therapy, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 24, 2026, 5:02 AM EDT
Completed No phase listed Observational

A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer

NCT02888366
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Montclair, New Jersey • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 24, 2026, 5:02 AM EDT
Recruiting Phase 1 Interventional

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

NCT07513129
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, Lymphoma
Interventions
Venetoclax, Dexamethasone, Bortezomib, Daratumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 5:02 AM EDT